<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over the past few decades, self-monitoring of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (SMBG) has been recognized as a core component of effective <z:mp ids='MP_0002055'>diabetes</z:mp> self-management among insulin-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) patients </plain></SENT>
<SENT sid="1" pm="."><plain>Given the costly nature of current T2DM care, especially as the worldwide prevalence of T2DM continues to increase rapidly, it is critical to determine whether resources devoted to SMBG in non-insulin treated T2DM patients are also justified and being applied effectively </plain></SENT>
<SENT sid="2" pm="."><plain>We review the conflicting evidence on the use of SMBG in insulin-na√Øve T2DM patients </plain></SENT>
</text></document>